动脉瘤性蛛网膜下腔出血的宽松或限制性输血策略
该多中心随机对照试验纳入742例急性动脉瘤性蛛网膜下腔出血合并贫血的危重成人,分配至宽松策略(血红蛋白≤10 g/dL 强制输血)或限制性策略(血红蛋白≤8 g/dL 可选输血)。主要终点为12个月改良Rankin量表评分≥4分的不良神经功能结局,宽松组122/364例(33.5%)vs 限制性组136/361例(37.7%)(RR 0.88;95%CI 0.72-1.09;P=0.22)。12个月功能独立性(FIM)、生活质量(EQ-5D-5L效用指数与VAS)及不良事件发生率两组相似。结论:宽松输血策略未较限制性策略降低12个月不良神经功能结局风险。
要点
- 742例动脉瘤性蛛网膜下腔出血合并贫血危重成人随机分至宽松策略(血红蛋白≤10 g/dL 强制输血)或限制性策略(血红蛋白≤8 g/dL 可选输血)。
- 12个月改良Rankin量表评分≥4分的不良神经功能结局:宽松组122/364例(33.5%)vs 限制性组136/361例(37.7%),RR 0.88(95%CI 0.72-1.09),P=0.22。
- 12个月FIM评分宽松组82.8±54.6 vs 限制性组79.8±54.5,均值差3.01(95%CI -5.49至11.51)。
- EQ-5D-5L效用指数两组均为0.5±0.4,均值差0.02(95%CI -0.04至0.09);VAS评分宽松组52.1±37.5 vs 限制性组50±37.1,均值差2.08(95%CI -3.76至7.93)。
- 两组不良事件发生率相似。
适用人群与场景
- 急性动脉瘤性蛛网膜下腔出血合并贫血的危重成人,在重症监护期间接受输血策略评估。
诊断标准与关键阈值
- 宽松策略:血红蛋白水平≤10 g/dL 时强制输血。
- 限制性策略:血红蛋白水平≤8 g/dL 时可选输血。
- 主要终点不良神经功能结局定义为12个月时改良Rankin量表评分≥4分(评分范围0-6分,分数越高残疾越重)。
处置流程与药物剂量
- 宽松策略组在血红蛋白≤10 g/dL 时强制输血。
- 限制性策略组在血红蛋白≤8 g/dL 时可选输血。
研究设计与关键结果
- 多中心随机对照试验,742例患者随机,来自23个中心;主要终点分析纳入725例(97.7%)。
- 12个月不良神经功能结局(改良Rankin量表≥4分):宽松组122/364例(33.5%)vs 限制性组136/361例(37.7%),风险比0.88(95%CI 0.72-1.09;P=0.22)。
- 12个月FIM评分:宽松组82.8±54.6 vs 限制性组79.8±54.5,均值差3.01(95%CI -5.49至11.51)。
- EQ-5D-5L效用指数:两组均为0.5±0.4,均值差0.02(95%CI -0.04至0.09)。
- VAS评分:宽松组52.1±37.5 vs 限制性组50±37.1,均值差2.08(95%CI -3.76至7.93)。
- 不良事件发生率两组相似。
证据类型、等级与局限
- 随机对照试验(SAHARA,ClinicalTrials.gov NCT03309579),由加拿大健康研究院等资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在动脉瘤性蛛网膜下腔出血合并贫血的危重成人中,宽松输血策略(血红蛋白≤10 g/dL 强制输血)未较限制性策略(血红蛋白≤8 g/dL 可选输血)降低12个月不良神经功能结局风险,两组功能独立性与生活质量及不良事件相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of a liberal red-cell transfusion strategy as compared with a restrictive strategy in patients during the critical care period after an aneurysmal subarachnoid hemorrhage is unclear.
METHODS: We randomly assigned critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia to a liberal strategy (mandatory transfusion at a hemoglobin level of ≤10 g per deciliter) or a restrictive strategy (optional transfusion at a hemoglobin level of ≤8 g per deciliter). The primary outcome was an unfavorable neurologic outcome, defined as a score of 4 or higher on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability), at 12 months. Secondary outcomes included 12-month functional independence as assessed with the Functional Independence Measure (FIM; scores range from 18 to 126) and quality of life as assessed with the EuroQol five-dimension, five-level (EQ-5D-5L) utility index (scores range from -0.1 to 0.95) and a visual analogue scale (VAS; scores range from 0 to 100); on each assessment, higher scores indicate better health status or quality of life.
RESULTS: A total of 742 patients underwent randomization at 23 centers. The analysis of the primary outcome at 12 months included 725 patients (97.7%). An unfavorable neurologic outcome occurred in 122 of 364 patients (33.5%) in the liberal-strategy group and in 136 of 361 patients (37.7%) in the restrictive-strategy group (risk ratio, 0.88; 95% confidence interval [CI], 0.72 to 1.09; P = 0.22). The mean (±SD) FIM score was 82.8±54.6 in the liberal-strategy group and 79.8±54.5 in the restrictive-strategy group (mean difference, 3.01; 95% CI, -5.49 to 11.51). The mean EQ-5D-5L utility index score was 0.5±0.4 in both groups (mean difference, 0.02; 95% CI, -0.04 to 0.09). The mean VAS score was 52.1±37.5 in the liberal-strategy group and 50±37.1 in the restrictive-strategy group (mean difference, 2.08; 95% CI, -3.76 to 7.93). The incidence of adverse events was similar in the two groups.
CONCLUSIONS: In patients with aneurysmal subarachnoid hemorrhage and anemia, a liberal transfusion strategy did not result in a lower risk of an unfavorable neurologic outcome at 12 months than a restrictive strategy. (Funded by the Canadian Institutes of Health Research and others; SAHARA ClinicalTrials.gov number, NCT03309579.).
参考来源
- English SW, Delaney A, Fergusson DA, et al. Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage. N Engl J Med. 2024. PMID: 39655786. doi:10.1056/NEJMoa2410962
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。